Citation Impact
Citing Papers
Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes
2007
The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals
2022 StandoutNobel
Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study
2006
CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment
2005
Metabolic Drug Interactions Between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract
2011
Tamoxifen‐loaded thiolated alginate‐albumin nanoparticles as antitumoral drug delivery systems
2012
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
2009
Investigation of the Mechanisms Underlying the Differential Effects of the K262R Mutation of P450 2B6 on Catalytic Activity
2008
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment
2005
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
2012 Standout
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
2013 Standout
Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression
2003
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz
2005
Preparation of human metabolites of propranolol using laboratory‐evolved bacterial cytochromes P450
2005 StandoutNobel
Polymorphism of human cytochrome P450 enzymes and its clinical impact
2009
Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
2011
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
2005
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study
2011
Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen
2004
High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe
2007
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
2012
Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics
2017
Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy
2008
Antiproliferative activity of lignans against the breast carcinoma cell lines MCF 7 and BT 20
2011
Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects
2007
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants
2012
A Panel of Cytochrome P450 BM3 Variants to Produce Drug Metabolites and Diversify Lead Compounds
2009 StandoutNobel
Efavirenz in the therapy of HIV infection
2009
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
2009
Structures of Cytochrome P450 2B6 Bound to 4-Benzylpyridine and 4-(4-Nitrobenzyl)pyridine: Insight into Inhibitor Binding and Rearrangement of Active Site Side Chains
2011
Natural product-based nanoformulations for cancer therapy: Opportunities and challenges
2019 Standout
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
2008
CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
2012
Human hepatic CYP2B6 developmental expression: The impact of age and genotype
2009
Multiple Novel Nonsynonymous CYP2B6 Gene Polymorphisms in Caucasians: Demonstration of Phenotypic Null Alleles
2004
Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients
2011
Artificial intelligence in drug development: present status and future prospects
2018 Standout
Interpatient variability in the pharmacokinetics of the HIV non‐nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism
2005
Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2
2009
Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-infected Individuals
2007
Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin
2008 Standout
Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals
2009
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Kynurenines in the CNS: recent advances and new questions
2012
Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver
2008
CYP2B6983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment
2007
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
2009
Refined protocols of tamoxifen injection for inducible DNA recombination in mouse astroglia
2018
Metabolism of Efavirenz and 8-Hydroxyefavirenz by P450 2B6 Leads to Inactivation by Two Distinct Mechanisms
2006
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
A Natural CYP2B6 TATA Box Polymorphism (–82T→ C) Leading to Enhanced Transcription and Relocation of the Transcriptional Start Site
2005
Serotonin, tryptophan metabolism and the brain-gut-microbiome axis
2014 Standout
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6
2003
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
THE NATURALLY OCCURRING CYTOCHROME P450 (P450) 2B6 K262R MUTANT OF P450 2B6 EXHIBITS ALTERATIONS IN SUBSTRATE METABOLISM AND INACTIVATION
2005
Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine
2004
PharmGKB summary
2011
Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers
2006
Selective Induction of Human Hepatic Cytochromes P450 2B6 and 3A4 by Metamizole
2007
Q172H Replacement Overcomes Effects on the Metabolism of Cyclophosphamide and Efavirenz Caused by CYP2B6 Variant with Arg262
2011
Mining electronic health records: towards better research applications and clinical care
2012 Standout
Removal of cytostatic drugs from aquatic environment: A review
2013 Standout
Worldwide Distribution of Cytochrome P450 Alleles: A Meta‐analysis of Population‐scale Sequencing Projects
2017
Recent advances in research on lignans and neolignans
2016 Standout
Estrogen Receptors as Therapeutic Targets in Breast Cancer
2008
Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
2010
Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer
2010
Pharmacogenomics of Tamoxifen Therapy
2009
Worldwide Variation in Human Drug-Metabolism Enzyme GenesCYP2B6andUGT2B7: Implications for HIV/AIDS Treatment
2012
Influence of Liver Fibrosis Stage on Plasma Levels of Antiretroviral Drugs in HIV‐Infected Patients with Chronic Hepatitis C
2007
Piezo1 channels restrain regulatory T cells but are dispensable for effector CD4 + T cell responses
2021 Standout
Trace determination of tamoxifen and 5-fluorouracil in hospital and urban wastewaters
2006
Long oligonucleotide microarrays for African green monkey gene expression profile analysis
2007 StandoutNobel
In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450
2017
Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study
2018 StandoutNobel
Identification of Mechanism-Based Inactivation in P450-Catalyzed Cyclopropanation Facilitates Engineering of Improved Enzymes
2016 StandoutNobel
ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties
2021 Standout
Clinical impact of patient population differences and genomic variation in efavirenz therapy
2008
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.
2004
Mechanism-Based Inactivation of Human Cytochromes P450s: Experimental Characterization, Reactive Intermediates, and Clinical Implications
2007
Coprescription of Tamoxifen and Medications That Inhibit CYP2D6
2010
Mechanism of Oxidation Reactions Catalyzed by Cytochrome P450 Enzymes
2004 Standout
Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV‐infected patients in Uganda
2007
PolymorphicCYP2B6: Molecular Mechanisms and Emerging Clinical Significance
2007
Pharmacogenetics of Anti-HIV Drugs
2007
Works of Bryan A. Ward being referenced
Diindolylmethane inhibits indoleamine 2,3-dioxygenase activity in breast cancer cells
2005
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole
2010
Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial
2003
The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity
2003
Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6
2004
Impact of CYP2B6 Polymorphism on Hepatic Efavirenz Metabolismin Vitro
2007